Unknown

Dataset Information

0

Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.


ABSTRACT: BACKGROUND:Peanut sublingual immunotherapy (SLIT) for 1 year has been shown to induce modest clinical desensitization in allergic children. Studies of oral immunotherapy, epicutaneous immunotherapy, and SLIT have suggested additional benefit with extended treatment. OBJECTIVE:We sought to investigate the safety, clinical effectiveness, and immunologic changes with long-term SLIT in children with peanut allergy. METHODS:Children with peanut allergy aged 1 to 11 years underwent extended maintenance SLIT with 2 mg/d peanut protein for up to 5 years. Subjects with peanut skin test wheals of less than 5 mm and peanut-specific IgE levels of less than 15 kU/L were allowed to discontinue therapy early. Desensitization was assessed through a double-blind, placebo-controlled food challenge (DBPCFC) with up to 5000 mg of peanut protein after completion of SLIT dosing. Sustained unresponsiveness was further assessed by using identical DBPCFCs after 2 to 4 weeks without peanut exposure. RESULTS:Thirty-seven of 48 subjects completed 3 to 5 years of peanut SLIT, with 67% (32/48) successfully consuming 750 mg or more during DBPCFCs. Furthermore, 25% (12/48) passed the 5000-mg DBPCFC without clinical symptoms, with 10 of these 12 demonstrating sustained unresponsiveness after 2 to 4 weeks. Side effects were reported with 4.8% of doses, with transient oropharyngeal itching reported most commonly. Side effects requiring antihistamine treatment were uncommon (0.21%), and no epinephrine was administered. Peanut skin test wheals, peanut-specific IgE levels, and basophil activation decreased significantly, and peanut-specific IgG4 levels increased significantly after peanut SLIT. CONCLUSION:Extended-therapy peanut SLIT provided clinically meaningful desensitization in the majority of children with peanut allergy that was balanced with ease of administration and a favorable safety profile.

SUBMITTER: Kim EH 

PROVIDER: S-EPMC6842439 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.

Kim Edwin H EH   Yang Luanna L   Ye Ping P   Guo Rishu R   Li Quefeng Q   Kulis Michael D MD   Burks A Wesley AW  

The Journal of allergy and clinical immunology 20190904 5


<h4>Background</h4>Peanut sublingual immunotherapy (SLIT) for 1 year has been shown to induce modest clinical desensitization in allergic children. Studies of oral immunotherapy, epicutaneous immunotherapy, and SLIT have suggested additional benefit with extended treatment.<h4>Objective</h4>We sought to investigate the safety, clinical effectiveness, and immunologic changes with long-term SLIT in children with peanut allergy.<h4>Methods</h4>Children with peanut allergy aged 1 to 11 years underwe  ...[more]

Similar Datasets

| S-EPMC3052379 | biostudies-literature
| S-EPMC4527157 | biostudies-literature
| S-EPMC4732904 | biostudies-literature
| S-EPMC3550002 | biostudies-literature
| S-EPMC2731305 | biostudies-literature
| S-EPMC5369605 | biostudies-literature
2022-08-10 | GSE196495 | GEO
| S-EPMC6494514 | biostudies-literature
| S-EPMC9356972 | biostudies-literature
| S-EPMC3983904 | biostudies-other